Konstantinos T. Papazisis

Thessaloniki, ESYE12 54636, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Real-World Neoadjuvant Systemic Therapy Utilization and Treatment Patterns in Patients with Early-Stage or Locally Advanced Triple-Negative Breast Cancer in Greece-The TRINITY Study.

Real-World Neoadjuvant Systemic Therapy Utilization and Treatment Patterns in Patients with Early-Stage or Locally Advanced Triple-Negative Breast Cancer in Greece-The TRINITY Study.

Journal: Cancers

Published: October 24, 2025

Evaluation of the 1021-HRD assay compared to established HRD testing platforms in ovarian cancer.

Evaluation of the 1021-HRD assay compared to established HRD testing platforms in ovarian cancer.

Journal: Translational oncology

Published: May 26, 2025

Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use.

Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use.

Journal: International journal of molecular sciences

Published: April 23, 2025

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Journal: Nature medicine

Published: March 12, 2025

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study.

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study.

Journal: ESMO real world data and digital oncology

Published: January 04, 2025

The Role of the NOLUS Score in Predicting pCR and iDFS in HR-positive HER2-negative Early Breast Cancer Patients who Received Neoadjuvant Chemotherapy.

The Role of the NOLUS Score in Predicting pCR and iDFS in HR-positive HER2-negative Early Breast Cancer Patients who Received Neoadjuvant Chemotherapy.

Journal: Cancer diagnosis & prognosis

Published: August 09, 2024

The Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory.

The Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory.

Journal: Cancer genomics & proteomics

Published: June 26, 2024

Association of Oncotype-DX HER2 Single Gene Score With HER2 Expression Assessed by Immunohistochemistry in HER2-low Breast Cancer.

Association of Oncotype-DX HER2 Single Gene Score With HER2 Expression Assessed by Immunohistochemistry in HER2-low Breast Cancer.

Journal: Cancer diagnosis & prognosis

Published: March 24, 2024

Assessment of parameters associated with ovarian function recovery in premenopausal women with early breast cancer and chemotherapy-induced amenorrhea in real-world clinical practice.

Assessment of parameters associated with ovarian function recovery in premenopausal women with early breast cancer and chemotherapy-induced amenorrhea in real-world clinical practice.

Journal: European journal of obstetrics, gynecology, and reproductive biology

Published: February 12, 2024

Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study).

Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study).

Journal: BMC cancer

Published: January 24, 2024

Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing.

Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing.

Journal: Cancers

Published: September 19, 2023

Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing.

Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing.

Journal: Cancer genomics & proteomics

Published: May 29, 2023

Showing 1-12 of 37

Last Updated: 09/26/2026